Profile of alisporivir and its potential in the treatment of hepatitis C

References

• Dienstag JL McHutchison JG American Gastroenterological Association technical review on the management of hepatitis C Gastroenterology 2006 130 231 264 16401486
   PubMed Web of Science ®Google Scholar
• Alter MJ Epidemiology of hepatitis C virus infection World J Gastroenterol 2007 13 2436 2441 17552026
   PubMed Web of Science ®Google Scholar
• Soriano V Madejon A Vispo E Emerging drugs for hepatitis C Expert Opin Emerg Drugs 2008 13 1 19 18321145
   PubMed Web of Science ®Google Scholar
• Shepard CW Finelli L Alter MJ Global epidemiology of hepatitis C virus infection Lancet Infect Dis 2005 5 558 567 16122679
   PubMed Web of Science ®Google Scholar
• Armstrong GL Wasley A Simard EP McQuillan GM Kuhnert WL Alter MJ The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 2006 144 705 714 16702586
   PubMed Web of Science ®Google Scholar
• Sy T Jamal MM Epidemiology of hepatitis C virus (HCV) infection Int J Med Sci 2006 3 41 46 16614741
   PubMedGoogle Scholar
• Tong MJ Reddy KR Lee WM Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group Hepatology 1997 26 747 754 9303508
   PubMed Web of Science ®Google Scholar
• Cross TJ Antoniades CG Harrison PM Current and future management of chronic hepatitis C infection Postgrad Med J 2008 84 172 176 18424572
   PubMed Web of Science ®Google Scholar
• Simmonds P Bukh J Combet C Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes Hepatology 2005 42 962 973 16149085
   PubMed Web of Science ®Google Scholar
• Manns MP Wedemeyer H Cornberg M Treating viral hepatitis C: efficacy, side effects, and complications Gut 2006 55 1350 1359 16905701
   PubMed Web of Science ®Google Scholar
• Global Surveillance and Control of Hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium J Viral Hepat 1999 6 35 47 10847128
   PubMed Web of Science ®Google Scholar
• Borel JF History of the discovery of cyclosporin and of its early pharmacological development Wien Klin Wochenschr 2002 114 433 437 12422576
   PubMed Web of Science ®Google Scholar
• Inoue K Sekiyama K Yamada M Watanabe T Yasuda H Yoshiba M Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial J Gastroenterol 2003 38 567 572 12825133
   PubMed Web of Science ®Google Scholar
• Inoue K Yoshiba M Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease Transplant Proc 2005 37 1233 1234 15848679
   PubMed Web of Science ®Google Scholar
• Goto K Watashi K Murata T Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811 Biochem Biophys Res Commun 2006 343 879 884 16564500
   PubMed Web of Science ®Google Scholar
• Ishii N Watashi K Hishiki T Diverse effects of cyclosporine on hepatitis C virus strain replication J Virol 2006 80 4510 4520 16611911
   PubMed Web of Science ®Google Scholar
• Nakagawa M Sakamoto N Enomoto N Specific inhibition of hepatitis C virus replication by cyclosporin A Biochem Biophys Res Commun 2004 313 42 47 14672695
   PubMed Web of Science ®Google Scholar
• Watashi K Hijikata M Hosaka M Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes Hepatology 2003 38 1282 1288 14578868
   PubMed Web of Science ®Google Scholar
• Ma S Boerner JE TiongYip C NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon Antimicrob Agents Chemother 2006 50 2976 2982 16940091
   PubMed Web of Science ®Google Scholar
• Paeshuyse J Kaul A De Clercq E The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro Hepatology 2006 43 761 770 16557546
   PubMed Web of Science ®Google Scholar
• Hopkins S Scorneaux B Huang Z SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro Antimicrob Agents Chemother 2010 54 660 672 19933795
   PubMed Web of Science ®Google Scholar
• Coelmont L Kaptein S Paeshuyse J Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors Antimicrob Agents Chemother 2009 53 967 976 19104013
   PubMed Web of Science ®Google Scholar
• Inoue K Umehara T Ruegg UT Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo Hepatology 2007 45 921 928 17393519
   PubMed Web of Science ®Google Scholar
• Grisé H Frausto S Logan T Tang H A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates alisporivir susceptibility J Virol 2012 86 4811 4822 22345441
   PubMed Web of Science ®Google Scholar
• Kaul A Stauffer S Berger C Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics PLoS Pathog 2009 5 e1000546 19680534
   PubMed Web of Science ®Google Scholar
• Flisiak R Horban A Gallay P The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus Hepatology 2008 47 817 826 18302285
   PubMed Web of Science ®Google Scholar
• Herrmann E Kafer A Flisiak R Nicolas-Metral V Zeuzem S Crabbe R PK-PD modeling of viral kinetics during treatment with Debio-025 plus pegylated interferon α-2a in treatment-naive HCV patients J Hepatol 2009 50 S1 S344
   Web of Science ®Google Scholar
• Flisiak R Feinman SV Jablkowski M The cyclophilin inhibitor debio 025 combined with Peg-IFN2a significantly reduces viral load in treatment naïve hepatitis C patients Hepatology 2009 49 1460 1468 19353740
   PubMed Web of Science ®Google Scholar
• Flisiak R Pawlotsky JM Crabbe R Once daily alisporivir (DEB025) plus peg-IFN-alfa-2a/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment-naïve patients – the ESSENTIAL study J Hepatol 2011 55 Abstract 190
   Google Scholar
• Pawlotsky JM Sarin SK Foster GR Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-G2 or G3 patients: SVR12 results from VITAL-1 phase 2b study J Hepatol 2012 56 Abstract 1405
   Web of Science ®Google Scholar
• Pawlotsky JM Sarin SK Foster GR Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1study Abstract 233 presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA November 9–12, 2012
   Google Scholar
• Alberti M Chuang WL Flisiak R Alisporivir (ALV) plus peg-interferon/ribavirin (PR) in HCV G1 treatment-experienced patients achieves primary endpoint with superior efficacy at treatment week 12 compared to retreatment with PR J Hepatol 2012 56 Abstract 1406
   Web of Science ®Google Scholar
• Davis G Kao J Alberti A Alisporivir (ALV) plus peg-interferon/ribavirin (P/R) achieves high on-treatment undetectable HCV RNA levels among the most difficult to treat HCV G1 patients. Results of a planned treatment week 24 interim analysis of a randomized, double blind, placebo controlled trial (FUNDAMENTAL study) Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA November 9–12, 2012
   Google Scholar
• Chatterji U Bobardt MD Selvarajah S The isomerase active site of cyclophilin A is critical for hepatitis C virus replication J Biol Chem 2009 284 16998 17005 19380579
   PubMed Web of Science ®Google Scholar
• Liu Z Yang F Robotham JM Tang H Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex J Virol 2009 83 6554 6565 19386705
   PubMed Web of Science ®Google Scholar
• Ke HM Zydowsky LD Liu J Walsh CT Crystal structure of recombinant human T-cell cyclophilin A at 2.5 A resolution Proc Natl Acad Sci U S A 1991 88 9483 9487 1946361
   PubMed Web of Science ®Google Scholar
• Zydowsky LD Etzkorn FA Chang HY Active site mutants of human cyclophilin a separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition Protein Sci 1992 1 1092 1099 1338979
   PubMed Web of Science ®Google Scholar
• Hanoulle X Badillo A Wieruszeski JM Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B J Biol Chem 2009 284 13589 13601 19297321
   PubMed Web of Science ®Google Scholar
• Fernandes F Ansari IU Striker R Cyclosporine inhibits A direct interaction between cyclophilins and hepatitis c NS5A PLoS One 2010 5 e9815 20352119
   PubMed Web of Science ®Google Scholar
• Chatterji U Lim P Bobardt MD HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors J Hepatol 2010 53 50 56 20451281
   PubMed Web of Science ®Google Scholar
• Coelmont L Hanoulle X Chatterji U DEB025 (alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A PLoS One 2010 5 e13687 21060866
   PubMed Web of Science ®Google Scholar
• Waller H Chatterji U Gallay P Parkinson T Targett-Adams PJ The use of alphalisa technology to detect interaction between hepatitis C virus-encoded ns5a and cyclophilin A Virol Methods 2010 165 202 210
   Web of Science ®Google Scholar
• Garcia-Rivera JA Bobardt MD Chatterji U Multiple mutations in HCV NS5A domain II are required to confer significant level of resistance to alisporivir Antimicrob Agents Chemother 2012 56 5113 5121 22802259
   PubMed Web of Science ®Google Scholar
• Yang F Robotham JM Grise H A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach PLoS Pathog 2010 6 e1001118 20886100
   PubMed Web of Science ®Google Scholar
• Foster TL Gallay P Stonehouse NJ Harris M Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner J Virol 2011 85 7460 7464 21593166
   PubMed Web of Science ®Google Scholar
• Shirota Y Luo H Qin W Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (Rdrp) NS5B and modulates RNA-dependent RNA polymerase activity J Biol Chem 2002 277 11149 11155 11801599
   PubMed Web of Science ®Google Scholar
• He Y Staschke KA Tan SL HCV NS5A: A multifunctional regulator of cellular pathways and virus replication Tan SL Hepatitis C Viruses: Genomes and Molecular Biology Norfolk, UK Horizon Bioscience 2006
   Google Scholar
• Bobardt M Hopkins S Baugh J HCV NS5A and IRF9 compete for CypA binding J Hepatol 2013 58 16 23 22902549
   PubMed Web of Science ®Google Scholar
• Tiongyip C Jones CT Tang Y Host targeting cyclophilin inhibitor alisporivir presents a high barrier to resistance with no cross-resistance to direct acting antivirals Presented at the Sixth International Workshop on Hepatitis C, Resistance and New Compounds Cambridge, MA June 23–24, 2011
   Google Scholar
• Gane EJ Stedman CA Hyland RH Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: the ELECTRON trial Abstract 229 presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA November 9–13, 2012
   Google Scholar
• Sulkowski MS Gardiner DF Rodriguez-Torres M High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3 Abstract LB-2 presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA November 9–13, 2012
   Google Scholar
• Everson GT Sims KD Rodriguez-Torres M An interferon-free, ribavirin-free 12-week regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 yielded SVR4 of 94% in treatment-naive patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection Abstract LB-3 presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA November 9–13, 2012
   Google Scholar
• Kowdley KV Lawitz E Poordad F A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infection Abstract LB-1 presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA November 9–13, 2012
   Google Scholar
• Gao M Nettles RE Belema M Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 2010 465 96 100 20410884
   PubMed Web of Science ®Google Scholar
• Lemm JA O’Boyle D2nd Liu M J Virol 2010 84 482 491 19812153
   PubMed Web of Science ®Google Scholar